Avapritinib for Systemic Mastocytosis.

Abstract excerpt

INTRODUCTION: Systemic mastocytosis (SM) is a rare myeloid neoplasm driven in ≈95% of cases by activating KIT mutations, usually D816V. SM can be indolent (ISM), smoldering (SSM) and advanced (AdvSM), the latter characterized by organ damage resulting from infiltrating neoplastic mast cells. The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. AdvSM,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mast Cells
• Share to Mastocytosis
• Share to Mastocytosis, Systemic